InvestorsHub Logo
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Re: cheynew post# 191401

Tuesday, 09/23/2014 10:11:41 AM

Tuesday, September 23, 2014 10:11:41 AM

Post# of 346013
No I am not cherry picking. I take the PPHM PPS as it was maximum impacted by the dose switching events which was the event mentioned to pick 1.20$ in stead of 0.60$

If I was cherry picking I would have written we crawled out and even made 3+$ in March 2014, which would be a 500% increase compared to the dip to 0.63$ we came from due to the dose switching.

And what is Jan 7th 2014 to measure 28% against. Why the period we were hanging around 1.20$ and were doing to same complaining. Well we are 15% up since then too.

So you see, the PPS, as many have been posting since the last months, is a WORTHLESS measurement tool for companies that are not yet in a commercial phase with there core business because they have no steady revenue out of that business and hence nobody can measure their performance and in case of Bavituximab, a drug, if it is wanted our not.

But OK, if the PPS is actually the only thing one can point to then I think PPHM has an extremely strong case.

And as for this.
I'd say then at least no one will for once say that PPHM is only busy with stock, stock option plans etc to self serve and BoD/Management cannot self serve and forget the employees because at least at controlling and accounting they will know what is going on.

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News